An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
Clinical trial NCT03002376 · COMPLETED
Trial details
- NCT number
- NCT03002376
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-10
- Primary completion
- 2019-03-05
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.